Work in progress: clinical evaluation of Tc-99m-trimethylbromo-IDA and Tc-99m-diisopropyl-IDA for hepatobiliary imaging.
Six healthy individuals and six patients with a wide range of hepatobiliary function abnormalities were studied with Tc-99m-trimethylbromo-IDA; all normal subjects and four of the six patients were also studied with Tc-99m-diisopropyl-IDA. Visual evaluation of analog images demonstrated a greater liver-to-kidney ratio for Tc-99m-trimethylbromo-IDA (p less than 0.01). Sampling for radiopharmaceutical in urine at three hours following injection demonstrated that Tc-99m-trimethylbromo-IDA had a lower renal excretion rate than Tc-99m-diisopropyl-IDA regardless of whether hepatocyte function was normal or abnormal (p less than 0.01). There were no significant differences between the two radiopharmaceuticals in hepatocyte extraction efficiency or hepatic parenchymal transit time. It is concluded that the lower rate of renal excretion and, therefore, greater hepatocyte specificity of Tc-99m-trimethylbromo-IDA justifies expanded clinical trials and may make it the radiopharmaceutical of choice for hepatobiliary imaging.
D000328:Adult; D000814:Aniline Compounds; D001659:Biliary Tract / Q000000981:diagnostic imaging*; D001660:Biliary Tract Diseases / Q000000981:diagnostic imaging; D004341:Drug Evaluation; D005998:Glycine; D006801:Humans; D007098:Imino Acids / Q000378:metabolism; D008099:Liver / Q000000981:diagnostic imaging*; D008107:Liver Diseases / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds; D011877:Radionuclide Imaging; D013667:Technetium / Q000378:metabolism; D019785:Technetium Tc 99m Disofenin
D000814:Aniline Compounds; D007098:Imino Acids; D015609:Organotechnetium Compounds; D013667:Technetium; C034837:technetium Tc 99m mebrofenin; D019785:Technetium Tc 99m Disofenin; D005998:Glycine